MBCCOP - Medical College of Georgia Cancer Center

Summary

MBCCOP - Medical College of Georgia Cancer Center is a medical facility located in Augusta, Georgia. This center is recognized for care of Solid Tumors, Breast Cancer, Leukemia, Cancer, Acute Myelogenous Leukemia and other specialties. MBCCOP - Medical College of Georgia Cancer Center is involved with conducting 103 clinical trials across 244 conditions. There are 9 research doctors associated with this hospital, such as Sharad Ghamande, Jorge Cortes, MD, Vamsi Kota, MD, and Locke J. Bryan.

Top PIs

Clinical Trials running at MBCCOP - Medical College of Georgia Cancer Center

Cancer

Cervical Cancer

Acute Myeloid Leukemia

Non-Hodgkin's Lymphoma

Leukemia

Ovarian Cancer

Multiple Myeloma

Chronic Myeloid Leukemia

Acute Myelogenous Leukemia

Endometrial Cancer

TIVDAK

for Cervical Cancer

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease. * This study is seeking for participants who: Are willing to take all the required eye tests * Have not received TIVDAK before * Do not have any active eye issues. Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages: * before starting the treatment, * before each of the first 9 infusions * then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.

Recruiting

3 awards

Phase 4

1 criteria

Lurbinectedin + Doxorubicin

for Leiomyosarcoma

The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.

Recruiting

2 awards

Phase 3

18 criteria

Cell Therapy

for Non-Hodgkin's Lymphoma

This trial tests a new treatment where a patient's own immune cells are enhanced to fight difficult-to-treat lymphoma. It targets patients whose cancer hasn't responded to at least two other treatments. The modified cells aim to better recognize and attack the cancer. This new method improves the ability of the patient's immune cells to find and destroy cancer cells.

Recruiting

1 award

Phase 2

19 criteria